Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOTRADECOL vs DIFFERIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sotradecol (sodium tetradecyl sulfate) is a sclerosing agent that acts by irritating the intimal endothelium of veins, causing inflammation, thrombosis, and subsequent fibrosis, leading to occlusion of the treated vein.
Adapalene is a retinoid-like compound that binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene expression and normalizing differentiation and proliferation of follicular epithelial cells, reducing comedogenesis and inflammation.
Uncomplicated spider veins (telangiectasias) and reticular veins of the lower extremities,Small, uncomplicated varicose veins
FDA-approved for the topical treatment of acne vulgaris in patients aged 12 and older. Off-label uses include treatment of photodamage, keratosis pilaris, and actinic keratoses.
0.5 m L per injection site, multiple sites per session; maximum volume 10 m L per session; intravenous (sclerotherapy) administration; frequency every 4-6 weeks.
Apply a thin layer of 0.1% gel or cream to affected areas once daily in the evening.
Terminal elimination half-life approximately 5-6 hours; clinical effect persists longer due to local action at injection site
Terminal elimination half-life is approximately 14–22 hours; steady-state is achieved within 3–5 days.
Sodium tetradecyl sulfate is primarily metabolized in the liver via sulfation and glucuronidation, with involvement of hepatic enzymes such as sulfotransferases and UDP-glucuronosyltransferases (UGTs).
Adapalene is minimally metabolized in the skin; systemic absorption is low. Any absorbed drug is primarily metabolized in the liver via cytochrome P450 enzymes, likely CYP2C9 and CYP3A4, and excreted in bile as metabolites.
Primarily renal; <1% recovered as unchanged drug in urine; majority eliminated as metabolites via bile into feces
Primarily biliary/fecal (>95%) as unchanged drug and metabolites; renal excretion is negligible.
>90% bound to plasma proteins, primarily albumin
Highly protein-bound (>99%), mainly to plasma albumin and lipoproteins.
0.15-0.3 L/kg; reflects limited distribution primarily to plasma and interstitial space
Large volume of distribution (~14–16 L/kg), indicating extensive tissue binding and distribution.
Not applicable; administered via intradermal, intravenous, or endoscopic injection; not intended for oral administration
Topical absorption is minimal (<5% of applied dose); systemic bioavailability is negligible.
No specific dose adjustment provided in labeling; not studied in renal impairment; use caution in severe impairment.
No dose adjustment required for renal impairment.
No specific dose adjustment provided in labeling; caution in Child-Pugh class C due to potential for acute hepatic necrosis.
No dose adjustment required for hepatic impairment.
Safety and efficacy not established in pediatric patients (age <18 years).
Approved for acne vulgaris in patients aged 12 years and older: apply 0.1% gel or cream once daily. Safety and efficacy in children under 12 not established.
No specific dose adjustment required; consider comorbidities and overall health status.
No specific dose adjustment; use with caution due to increased risk of skin irritation and dryness in elderly skin.
Sotradecol injection is contraindicated for the treatment of patients with underlying arterial disease or with known allergy to the drug. Severe adverse reactions including anaphylaxis, pulmonary embolism, and tissue necrosis have been reported.
None.
Anaphylactic reactions; arterial injection causing tissue necrosis; pulmonary embolism; allergy to the drug; use with caution in patients with thrombophlebitis, hypercoagulable states, or chronic obstructive pulmonary disease; avoid extravasation.
Avoid application to cuts, abrasions, eczematous, or sunburned skin.,Avoid excessive exposure to sunlight and UV light; use sunscreen.,Possible local skin reactions: erythema, scaling, dryness, burning, pruritus; dose reduction or interruption may be necessary.,Use caution in patients with eczema.,Not for oral or ophthalmic use.
Known allergy to sodium tetradecyl sulfate; acute thrombophlebitis; severe chronic venous insufficiency; arterial disease; uncontrolled diabetes mellitus; sepsis; pregnancy; breastfeeding; incompetent perforating veins.
Hypersensitivity to adapalene or any component of the formulation. Not for use in patients with known sensitivity to retinoids.
No specific food interactions are known. Patients should maintain adequate hydration and avoid excessive alcohol intake, which may increase the risk of bleeding or thrombosis. No dietary restrictions are required.
No significant food interactions. However, high-fat meals may slightly increase systemic absorption; unlikely to be clinically relevant.
FDA Pregnancy Category C. No adequate human studies; animal studies show fetal harm. Use only if benefit outweighs risk. First trimester: potential teratogenicity. Second/third trimester: risk of fetal bradycardia, arrhythmias, or death due to systemic absorption if injected near cervix.
Pregnancy Category C. Animal studies show teratogenicity at high oral doses; topical exposure has minimal systemic absorption. First trimester: risk cannot be ruled out. Second/third trimester: limited data, avoid use. No adequate human studies.
Unknown excretion in human milk. Due to low systemic absorption after local injection, risk to breastfed infant is likely low. Caution recommended; M/P ratio not established.
Not recommended. Excretion into human milk unknown; low systemic absorption likely but risk to infant cannot be excluded. M/P ratio not established.
No dose adjustment required; however, use only when clearly needed. Systemic absorption is minimal after local injection, and pharmacokinetic changes in pregnancy are unlikely to alter efficacy or safety.
Discontinue use. No dosage adjustment studies; topical application is contraindicated regardless of pharmacokinetic changes.
Sotradecol (sodium tetradecyl sulfate) is a sclerosing agent used for the treatment of varicose veins. Administer via direct injection into the vein using a fine needle; avoid extravasation as it causes tissue necrosis. Perform a test dose (0.5 m L) to assess for hypersensitivity. Compression stockings should be worn for 1-3 weeks post-injection. Do not exceed 10 m L per session; maximum total dose per session is 10 m L of 1% or 2 m L of 3% solution. Use caution in patients with arterial disease, recent thrombosis, or known hypersensitivity. Delayed skin pigmentation may occur. Allergic reactions, including anaphylaxis, have been reported.
Use a pea-sized amount for entire face to avoid irritation. Initiate with lower concentration (0.1% gel) for sensitive skin. Combination with benzoyl peroxide or topical antibiotics may enhance efficacy. Sunscreen is mandatory due to photosensitization. Do not apply to broken, eczematous, or sunburned skin.
This medication is injected directly into your varicose veins to cause them to collapse and fade.,You may experience a burning sensation at the injection site, which is normal.,Wear compression stockings as directed, typically for 1-3 weeks after treatment.,Avoid strenuous exercise and prolonged standing for 24-48 hours after injection.,Contact your doctor if you develop severe pain, swelling, redness, or skin ulcers at the injection site.,Notify your doctor if you have a history of blood clots, allergies, or are pregnant or breastfeeding.
Apply a thin layer once daily at bedtime to clean, dry skin.,Avoid excessive washing or using abrasive cleansers.,Use oil-free, non-comedogenic moisturizers and cosmetics.,Expect initial worsening of acne (retinoid reaction) which resolves in 4-6 weeks.,Sun protection (SPF 30+) and protective clothing are essential daily.,Minimize exposure to extreme wind or cold.,If pregnant, planning pregnancy, or breastfeeding, consult physician before use.,Keep away from eyes, mouth, nasal angles, and mucous membranes.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOTRADECOL vs DIFFERIN, answered by our medical review team.
SOTRADECOL is a Sclerosing agent that works by Sotradecol (sodium tetradecyl sulfate) is a sclerosing agent that acts by irritating the intimal endothelium of veins, causing inflammation, thrombosis, and subsequent fibrosis, leading to occlusion of the treated vein.. DIFFERIN is a Topical Retinoid that works by Adapalene is a retinoid-like compound that binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene expression and normalizing differentiation and proliferation of follicular epithelial cells, reducing comedogenesis and inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOTRADECOL and DIFFERIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOTRADECOL is: 0.5 m L per injection site, multiple sites per session; maximum volume 10 m L per session; intravenous (sclerotherapy) administration; frequency every 4-6 weeks.. The standard adult dose of DIFFERIN is: Apply a thin layer of 0.1% gel or cream to affected areas once daily in the evening.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOTRADECOL and DIFFERIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOTRADECOL is classified as Category C. FDA Pregnancy Category C. No adequate human studies; animal studies show fetal harm. Use only if benefit outweighs risk. First trimester: potential teratogenicity. Second/third tri. DIFFERIN is classified as Category C. Pregnancy Category C. Animal studies show teratogenicity at high oral doses; topical exposure has minimal systemic absorption. First trimester: risk cannot be ruled out. Second/thi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.